Scarica l'app Stockscreener
28.60
0.18%
0.05
Precedente Chiudi:
$28.55
Aprire:
$28.76
Volume 24 ore:
811.11K
Relative Volume:
2.00
Capitalizzazione di mercato:
$1.45B
Reddito:
$413.05M
Utile/perdita netta:
$-27.67M
Rapporto P/E:
-50.98
EPS:
-0.561
Flusso di cassa netto:
$-30.75M
1 W Prestazione:
-0.07%
1M Prestazione:
+0.81%
6M Prestazione:
-20.33%
1 anno Prestazione:
-9.78%
Intervallo 1D:
$28.29
$29.00
Intervallo di 1 settimana:
$27.64
$29.54
Portata 52W:
$27.55
$40.71
Immunocore Holdings Plc Adr Stock (IMCR) Company Profile
Nome
Immunocore Holdings Plc Adr
Settore
Industria
Telefono
01235 5430281
Indirizzo
90 PARK DRIVE, OXFORDSHIRE
Compare IMCR vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMCR
Immunocore Holdings Plc Adr
|
28.60 | 1.45B | 413.05M | -27.67M | -30.75M | -0.561 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunocore Holdings Plc Adr Stock (IMCR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-16 | Downgrade | Jefferies | Buy → Hold |
| 2026-01-07 | Aggiornamento | UBS | Sell → Buy |
| 2025-10-31 | Iniziato | Wells Fargo | Overweight |
| 2025-09-18 | Ripresa | Guggenheim | Neutral |
| 2025-08-25 | Ripresa | Jefferies | Buy |
| 2025-05-27 | Iniziato | Deutsche Bank | Buy |
| 2024-12-13 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-11-11 | Downgrade | Mizuho | Outperform → Neutral |
| 2024-10-24 | Iniziato | UBS | Sell |
| 2024-10-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-04-29 | Iniziato | Leerink Partners | Outperform |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-11-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-31 | Iniziato | Robert W. Baird | Outperform |
| 2023-09-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-09-13 | Iniziato | Needham | Buy |
| 2023-08-16 | Iniziato | CapitalOne | Overweight |
| 2023-07-17 | Iniziato | Canaccord Genuity | Hold |
| 2023-03-31 | Iniziato | Mizuho | Buy |
| 2023-03-30 | Iniziato | Guggenheim | Buy |
| 2023-03-24 | Iniziato | Bryan Garnier | Buy |
| 2022-12-16 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-11-30 | Iniziato | Barclays | Overweight |
| 2022-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2022-09-08 | Iniziato | Ladenburg Thalmann | Buy |
| 2022-08-08 | Iniziato | Cowen | Outperform |
| 2022-08-02 | Iniziato | BTIG Research | Buy |
| 2022-02-08 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-20 | Iniziato | Oppenheimer | Outperform |
| 2021-03-02 | Iniziato | Goldman | Neutral |
| 2021-03-02 | Iniziato | JP Morgan | Overweight |
| 2021-03-02 | Iniziato | Jefferies | Buy |
Mostra tutto
Immunocore Holdings Plc Adr Borsa (IMCR) Ultime notizie
PFE Stock Slides Following CFO Exit, 2026 Guidance Reaffirmed - TradingView
JAZZ & ABCL Team Up to Develop Next-Generation Solid Tumor Therapies - TradingView
Is it a Good Idea to Invest in Immunocore Stock Right Now? - Yahoo Finance
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised) - TradingView
NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up - TradingView
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review - TradingView
INDV Stock: What Sublocade Growth Signals for 2026 - TradingView
GSK's Momelotinib Gets Orphan Tag for Rare Hemato-Inflammatory Disorder - TradingView
Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why - TradingView
HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US - TradingView
Sanofi Ends Late-Stage Study on Neurology Drug Over Weak Results - TradingView
ALVO Stock Gains 19% on FDA Resubmission of Biosimilar BLAs - TradingView
RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week? - TradingView
Kodiak Stock Rises 35% in 3 Months: Here's What You Need to Know - TradingView
ADCT Stock Plunges on Safety Concerns Despite Positive Lymphoma Data - TradingView
Amgen Secures EU Nod for Imdylltra in Lung Cancer Indication - TradingView
MRNA Partners With CEPI to Develop Vaccine for Bundibugyo Ebolavirus - TradingView
IMCR Stock Price, Quote & Chart | IMMUNOCORE HOLDINGS PLC-ADR (NASDAQ:IMCR) - ChartMill
REPL Stock Soars on Plans of BLA Resubmission for Melanoma Combo Drug - TradingView
AGIO Halts Tebapivat Development in Myelodysplastic Syndromes - TradingView
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma - GlobeNewswire Inc.
Immunocore reports Phase 1 data for melanoma drug brenetafusp - Investing.com
TGTX's Single-Dose Briumvi Hits Bioequivalence Goal in MS Study - TradingView
Dyne Therapeutics Stock Gains 4.5% After BLA Filing for DMD Therapy - TradingView
AGIO's Pyrukynd Gets Approval for Thalassemia in Europe - TradingView
Wall Street analysts think Immunocore (IMCR) could surge 111.53%: Read this before placing a bet - MSN
69,271 ADRs sale scheduled by Immunocore (NASDAQ: IMCR) - Stock Titan
Here's Why You Should Add Altimmune Stock to Your Portfolio Now - TradingView
Wall Street Analysts Think Immunocore (IMCR) Could Surge 111.53%: Read This Before Placing a Bet - Yahoo Finance
Immunocore Holdings (NASDAQ: IMCR) plans 65,000 ADR cashless sale - Stock Titan
Dyne Stock Gains 10% on Initiation of Late-Stage Study in DMD Patients - TradingView
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now? - TradingView
ATRA Stock Shoots Up 82% in a Month: Here's What You Should Know - TradingView
ERNA Stock Shoots Up 140% in a Month: Here's What You Should Know - TradingView
BMRN Stock Down on Mixed Results From Rare Disease Therapy Study - TradingView
FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy - TradingView
Bayer Gets FDA Priority Review for Asundexian NDA in Stroke Prevention - TradingView
Roche's Tecentriq Wins FDA Nod for Label Expansion in Bladder Cancer - TradingView
CRMD Q1 Earnings Beat on DefenCath Momentum, Guidance Raised - TradingView
T. Rowe Price (IMCR) holds 1.89M ADRs, files Schedule 13G/A amendment - Stock Titan
Immunocore Holdings stock (GB00BL963Z95): Recent price dip amid biotech trends - AD HOC NEWS
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y - TradingView
Mizuho cuts Immunocore stock price target to $34 on trimmed revenue - Investing.com
IMCR SEC FilingsImmunocore Holdings Plc 10-K, 10-Q, 8-K Forms - Stock Titan
Jefferies raises Immunocore stock price target on melanoma trial - Investing.com
Hussman Strategic Advisors Inc. Purchases Shares of 42,000 Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Immunocore (IMCR) upgraded to strong buy: Here's why - MSN
Q1 Earnings Forecast for Immunocore Issued By HC Wainwright - MarketBeat
Massachusetts Financial Services Co. MA Trims Holdings in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Immunocore (NASDAQ: IMCR) outlines 10 resolutions for 2026 hybrid AGM - Stock Titan
Immunocore Holdings Plc Adr Azioni (IMCR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):